Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen discovers possible new target for Parkinson’s drugs
This research is the first to suggest that inhibiting the Nogo-66 receptor (NgR1) may provide therapeutic benefit in the treatment of Parkinson’s disease. Parkinson’s disease is a chronic
This research is the first to suggest that inhibiting the Nogo-66 receptor (NgR1) may provide therapeutic benefit in the treatment of Parkinson’s disease. Parkinson’s disease is a chronic
Although the terms of the agreement were not revealed, Iconix said it will receive compensation from Lilly in exchange for access to its DrugMatrix chemogenomics system and its
Beta-amyloid is the major component of the plaques found in brains of Alzheimer’s disease patients and is implicated in the development and progression of this condition. Beta-amyloid has
VesCell uses adult stem cells derived from a patient’s own blood rather than his or her bone marrow. According to the data, 93% of patients given VesCell treatment
A total of 283 patients participated in the phase II study designed to evaluate the safety, optimal dosing and efficacy of LymphoStat-B (belimuma) in patients with active moderate-to-severe
A new chemical entity, ENMD-1198 is based on a modified chemical structure of 2-methoxyestradiol (2ME2) and is designed to decrease metabolism while retaining 2ME2’s multiple mechanisms of action.
ZIO-101, a novel organic arsenic, has demonstrated safety at doses approximately 25 times higher than the currently approved dose for arsenic trioxide, an inorganic arsenic currently approved for
The three separate studies of Modrenal (trilostane) will investigate the efficacy of the treatment in three distinct settings: a phase IV trial in advanced, post-menopausal breast cancer; a
The study demonstrated that the addition of the drug to radiation resulted in a 9.5 month improvement in median duration of locoregional control, or the prevention of the
The phase II trial in patients with non-small cell lung cancer (NSCLC) evaluating BLP25 Liposome Vaccine (L-BLP25) showed that the new formulation of the vaccine is not different